Alzheimer's disease (AD) is characterized by abnormal brain deposits of amyloid b and neurofibrillary tangles with hyperphosphorylated tau and by loss of synapses [1] . There is a complex relationship between brain protein processing and synaptic functioning [2] . New AD models suggest that abnormal protein deposits and synaptic dysfunction occur many years before AD dementia is diagnosed [3, 4] . Different neuroimaging measurements are taken as biomarkers in AD models. Yet a reliable neuroimaging measure of synaptic loss is still needed.
Synaptic vesicle protein 2A (SV2A) is a glycoprotein present in the membranes of most brain synaptic vesicles. Its physiological role is still debated [5] . SV2A is the therapeutic target of levetiracetam, an antiepileptic drug modifying the natural course of epilepsy in several models [6] . The role of SV2A in AD is particularly interesting. SV2A has been found to be reduced postmortem in the hippocampal structures of patients with dementia [7] . Levetiracetam restored dysfunctional networks in a mouse model of AD [8] . Moreover, it improved cognition and decreased hippocampal hyperactivity in patients in the predementia stage of AD [9] .
[ 18 F]UCB-H is an original biomarker showing binding specificity for SV2A ( [10, 11] ; Supplementary Data). In a rat microPET (micro positron emission tomography) study, the total distribution volume (Vt) of [ 18 F]UCB-H in the brain was calculated and the test-retest reproducibility was about 10% [11] . Levetiracetam induced dosedependent blocking and displacement of cerebral [ 18 F]UCB-H uptake. Radiodosimetry was performed in mice [12] and humans [13] . In this study of [ 18 F]UCB-H in healthy volunteers, we characterized its blood-brain pharmacokinetics. SV2A is a suitable marker of synaptic density, and we discuss its brain distribution and modeling properties compared to the recently published SV2A tracer [ 11 C]UCB-J [14] . SV2A is ubiquitous in the brain. There is no "reference region" without binding sites for [ 18 F]UCB, and an arterial blood input function (arterial input function [AIF] ) is required for quantifying regional distribution of the radiotracer. An original method using image-derived carotid artery activity is shown to be comparable to classical modeling with AIF.
Methods

Participants
Two young (38 and 46 years) and two senior (66 and 69 years) healthy male volunteers participated in this study (EudraCT 2011-003413-42). Subjects' suitability for participation was determined by interview, physical examination, clinical blood laboratory tests, 12-lead electrocardiogram, and urine drug screening (see Supplementary Data for inclusion/exclusion criteria). The study was approved by the Ethics Committee of Liege University Hospital (Belgium). All participants signed an informed consent form.
Image acquisition
Dynamic PET acquisitions were performed using a Siemens/CTI (Knoxville, TN) ECAT HR1 PET scanner. About 170.4 6 24.9 MBq of [ 18 F]UCB-H was injected as an intravenous bolus. The timeframe of the dynamic PET was 6 ! 10, 8 ! 30, 5 ! 120 and 17 ! 300 seconds, resulting in 100-minutes scanning time. All PET images were reconstructed using filtered backprojection including corrections for measured attenuation, dead time, random events, and scatter using standard software (ECAT 7.1, Siemens/CTI, Knoxville, TN). A structural magnetic resonance imaging (MRI) image acquired for each subject a few days before PET study (3-10 days) was used to exclude any brain abnormality and to facilitate coregistration of PET data to the standard Montreal Neurological Institute space for brain structures segmentation. MRI data were acquired on a 3T Allegra Siemens scanner (three-dimensional modified driven equilibrium Fourier transform [MDEFT] sequence) with the following parameters: TR 5 7.92 ms, TE 5 2.4 ms, TI 5 910 ms, FA 5 15 , FOV 5 256 ! 224 ! 176 mm 3 , and isotropic spatial resolution 5 1 mm.
Image quantification
In our analysis plan, we first searched for a suitable input function (IF), and we then searched for a suitable modeling approach.
To measure AIF, blood samples were collected through a cubital artery cannula. AIF was obtained by correcting plasma data for the unchanged tracer fraction determined using high performance liquid chromatography ( [11] ; Supplementary Data).
However, an arterial cannula cannot be used to study patient cohorts. Since brain SV2A is ubiquitous, it is improbable that a suitable reference region can be found to model radiotracer distribution. Here, we derived IF from dynamic PET images (image-derived input function [IDIF]) using the method described by Schain et al. [15] . The method extracts time series of [ 18 F]UCB-H in the carotid artery by identifying voxels belonging to the carotid. This is based on the computation of the Pearson product-moment correlation coefficient between a "seeding region" (a group of voxels in the carotid) and voxels in a mask containing the carotid (except those used as the seeding region). The extracted time series (IDIF) was then scaled to plasma radioactivity using the last three blood samples and corrected using mean unchanged plasma fractions. The detailed method is reported as Supplementary Data.
PET data were processed with SPM12 (Wellcome Department of Cognitive Neurology, London, UK). For each subject, PET dynamic frames were corrected for movement. The structural MRI image was coregistered to its PET image (sum of the dynamic data) without reslicing. The resulting MRI image was segmented and normalization transformation parameters (forward and inverse: transformation parameters used to bring images to the Montreal Neurological Institute stereotactic space) were calculated. The inverse transformation was used to bring the Automated Anatomical Labeling (AAL) human brain atlas into the PET subject space and extract the time activity curves of all AAL brain atlas regions. Kinetic modeling using both AIF and IDIF was done with PMOD (Version 3.7, PMOD Technologies, Zurich, Switzerland). Since the AAL atlas did not contain white matter (WM) regions, a centrum semiovale region was created using SPM WM probability map. This map was thresholded (.99.6%) to obtain only voxels with the highest WM membership. 
Statistical analyses
The similarity between AIF and IDIF was assessed by comparing the area under the curve, searching for a ratio around 1. Moreover, IFs were also fitted using a biexponential model, and the slopes of the IFs were compared using a nonparametric Wilcoxon test. Three kinetic models, 1-tissue compartment (1TC), 2-tissue compartment (2TC), and Logan graphical analysis were used to calculate the Vt of [ 
Results
PET images averaged over 100 minutes (Fig. 1) revealed a heterogeneous but ubiquitous tracer uptake in subcortical and cortical gray matter regions. [ 18 F]UCB-H brain kinetics were rapid, with an initial high uptake and a standardized uptake value peak (expressed as brain activity normalized to injected dose and body weight) of 5 to 10 across brain regions 10 minutes after injection, followed by rapid decline in regional radioactivity over time (Fig. 2) .
Blood data analysis showed a consistent tracer amount in whole blood and plasma indicating low binding to red blood cells. Unchanged [ 18 F]UCB-H fraction in plasma followed a 3-exponential decrease with a starting fraction of 97 6 2% (mean 6 SD) measured 3 minutes after injection. This fraction was subsequently measured at 5, 15, 35, 60, and 90 minutes and decreased to 85 6 17%, 37 6 14%, 30 6 13%, 21 6 8%, and 17 6 8%, respectively. Scaled IDIF was found to be very similar to AIF, with a mean ratio of area under the curve of 1.02 6 0.08. This was true for plasma and whole blood AIF (Table 1) . Moreover, the comparison of slope constants of the biexponential fit for the IFs, which provide an indication of the instantaneous level of blood radioactivity, Abbreviations: AUCr, area under the curve ratio; COV, coefficient of variation; IF, input function; IDIF, image-derived IF scaled to three plasma last samples; MFB, measured full blood activity; plasma, measured plasma activity; S1 to S4, participants; SD, standard deviation. Abbreviations: IDIF, image-derived input function scaled to last three plasma samples; MFB, measured full blood activity; plasma, measured plasma activity; S1 to S4, participants; SD, standard deviation.
showed similar values for AIF and IDIF, especially for the second slope constant (Z 5 1.82, P . .06; Table 2 ).
The three kinetic models (1TC, 2TC, and Logan) led to a consistent estimation of Vt. The 1TC gave a weak fitting of the data (measurement did not lie on the model curve, R 2 : 0.95), whereas the 2TC model fitted the data well (R 2 : 0.98) and provided total and specific values for distribution volume of the tracer, but not for all regions (few failures to fit experimental data). In contrast, Logan graphical model provided reliable Vt estimates with suitable fits (R 2 : 0.99) and reasonable start time (t* ranged between 15 and 30 minutes). Thus, Logan graphical model was chosen as the preferential method for analysis of the data using both AIF and IDIF and with a t* of 25 minutes (mean value over all regions and subjects). An estimate of the IF delay was included in the model to optimize its fit. A high linear relationship (R 2 . 0.99; slope: 1.013 6 0.080) was observed between Vt values obtained with AIF and IDIF (Fig. 3) . Mean Vt values ranged from 4.3 mL/cm 3 in the centrum semiovale to 7.8 mL/cm 3 in the gyrus rectus for both AIF and IDIF analyses. The single reserve was that Vt coefficients of variation were moderately higher for IDIF (176 2%) than for AIF analysis (12 6 2%). Supplementary Fig. 1 depicts regional Vt in the left cerebral hemisphere. Vt showed increasing values from the WM to the cerebellum, hippocampus, parahippocampal gyrus, parietal cortex, precuneus, frontal regions, amygdala, anterior cingulate cortex, and putamen (Fig. 4) . Referring to Finnema et al.'s study with , we calculated binding potential (BP ND ) using WM as pseudo-reference (representing nondisplaceable free and nonspecific binding). Unexpectedly, older participants had a higher BP ND than younger ones (Fig. 4) .
Discussion
[ 18 F]UCB-H has been used as a biomarker for SV2A [11] . A recent publication using [
11 C]UCB-J (a similar derivative of levetiracetam) showed a correlation between in vivo brain radiotracer binding and postmortem measures of brain SV2A in a baboon study [14] . Full quantification of [ 18 F]UCB-H binding through kinetic modeling was possible in the absence of a reference region devoid of specific tracer binding [16] . [ 18 F]UCB-H was shown to have negligible amount of radiometabolites in the rat brain [17] . Although [ 18 F]UCB-H uptake observed in WM is relatively low, making it a candidate for a reference region in young people [14] , WM is altered by AD [18, 19] , calling into question the value of WM as a pseudo-reference for older participants. Moreover, [ 18 F]UCB-H binding in pons was displaced with levetiracetam at 10 mg/kg in rats [11] . Therefore, an image-derived carotid signal was preferred as the IF for complete kinetic modeling. The IDIF result closely matched the result derived by manual arterial blood sampling (the "gold standard").
[ 18 F]UCB-H brain uptake confirmed the ubiquitous cerebral distribution of SV2A [11, 14, 20] . A Logan graphical model was used to describe brain accumulation, whereas a 1TC was chosen for modeling [ 11 C]UCB-J [14] . Although the two tracers are quite similar, Vt values are higher with [
11 C]UCB-J (5-22 ml/cc) than with [ 18 F]UCB-H (3-10 ml/cc), whereas [ 18 F]UCB-H has a longer half-life for performing population studies. Investigation of [ 18 F]UCB-H distribution in medial temporal structures, the default mode network, and the anterior cingulate cortex would be particularly interesting to explore the temporal relationship between brain amyloid and tau pathology and brain synaptic loss in AD [4, 21] or study frontotemporal dementia [22] .
Owing to the demanding PET protocol (arterial blood sampling, very selective inclusion criteria), only four subjects were recruited for this study. The mean parent fraction was used to correct IFs for metabolites, and this profile should be measured in venous blood for different patient groups. The time activity curves suggest that scan duration, another limitation, might be reduced to 50 minutes while retaining appropriate "Logan-modeling" properties. Finally, image correction for partial volume effects should be discussed in any patient study.
In conclusion, our results suggest that [ 18 F]UCB-H is a good candidate as radiotracer for brain SV2A and can be used for human studies. IDIF was showed to be useful for quantitative studies without the need to arterial blood sampling.
